TIMP3 expression associates with prognosis in colorectal cancer and its novel arylsulfonamide inducer, MPT0B390, inhibits tumor growth, metastasis and angiogenesis.


Journal

Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395

Informations de publication

Date de publication:
2019
Historique:
received: 12 02 2019
accepted: 31 07 2019
entrez: 8 10 2019
pubmed: 8 10 2019
medline: 24 10 2020
Statut: epublish

Résumé

Tissue inhibitors of metalloproteinase 3 (TIMP3) are a major endogenous inhibitor of matrix metalloproteinase (MMPs) that inhibit tumor growth, invasion, metastasis and angiogenesis. In this study, we found that TIMP3 expression is associated with positive prognosis of colorectal cancer (CRC) clinicopathologically. Therefore, we developed a series of arylsulfonamide derivatives as

Identifiants

pubmed: 31588243
doi: 10.7150/thno.34020
pii: thnov09p6676
pmc: PMC6771239
doi:

Substances chimiques

Angiogenesis Inhibitors 0
Antineoplastic Agents 0
Arylsulfonates 0
Biomarkers, Tumor 0
Indoles 0
TIMP3 protein, human 0
Tissue Inhibitor of Metalloproteinase-3 0
EZH2 protein, human EC 2.1.1.43
Enhancer of Zeste Homolog 2 Protein EC 2.1.1.43

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6676-6689

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© The author(s).

Déclaration de conflit d'intérêts

Competing Interests: The authors have declared that no competing interest exists.

Références

Oncogene. 2015 Jul 30;34(31):4098-108
pubmed: 25347747
Int J Biochem Cell Biol. 2008;40(6-7):1362-78
pubmed: 18258475
Breast Cancer Res. 2006;8(5):R57
pubmed: 17032447
J Med Chem. 2010 Jan 28;53(2):822-39
pubmed: 20017493
Int J Cancer. 2007 Aug 15;121(4):714-23
pubmed: 17455256
J Cell Sci. 2002 Oct 1;115(Pt 19):3719-27
pubmed: 12235282
Epigenetics. 2012 Nov;7(11):1279-89
pubmed: 23023649
Cytokine. 1997 Oct;9(10):770-80
pubmed: 9344510
Matrix Biol. 2015 May-Jul;44-46:247-54
pubmed: 25805621
Genome Biol. 2011 Nov 11;12(11):233
pubmed: 22078297
Structure. 2004 Jul;12(7):1325-34
pubmed: 15242608
Mol Ther. 2002 Jun;5(6):705-15
pubmed: 12027554
Oncogene. 2011 Jul 7;30(27):3011-23
pubmed: 21339735
J Biol Chem. 2000 Oct 6;275(40):31226-32
pubmed: 10900194
Apoptosis. 2015 Apr;20(4):523-34
pubmed: 25558000
Nat Med. 2003 Apr;9(4):407-15
pubmed: 12652295
Cancer Gene Ther. 2012 Dec;19(12):845-51
pubmed: 23037807
Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):15064-9
pubmed: 15477595
Oncol Rep. 2008 Dec;20(6):1489-95
pubmed: 19020732
Br J Cancer. 1999 Mar;79(9-10):1347-55
pubmed: 10188875
J Med Chem. 2003 Feb 27;46(5):820-30
pubmed: 12593661
Med Oncol. 2013 Dec;30(4):713
pubmed: 24132606
Circ Res. 2007 Mar 30;100(6):782-94
pubmed: 17395884
Chembiochem. 2013 Jul 8;14(10):1248-54
pubmed: 23788254
Cancer Res. 2000 Oct 15;60(20):5723-30
pubmed: 11059766
Appl Microbiol Biotechnol. 2007 Jun;75(3):487-97
pubmed: 17377789
Angiogenesis. 2014 Jan;17(1):163-77
pubmed: 24221409
PLoS One. 2014 Aug 29;9(8):e106161
pubmed: 25171061
Genes Dev. 2004 Nov 1;18(21):2596-601
pubmed: 15520279
J Med Chem. 2012 Apr 26;55(8):3777-91
pubmed: 22439863
Biochim Biophys Acta. 2010 Jan;1803(1):55-71
pubmed: 20080133
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Neoplasia. 2008 Jun;10(6):563-72
pubmed: 18516293
Prostate. 2015 Dec;75(16):1831-43
pubmed: 26332574
PLoS One. 2012;7(1):e30393
pubmed: 22272343
J Biol Chem. 2002 Apr 19;277(16):13787-95
pubmed: 11827969
Oncotarget. 2014 Oct 30;5(20):9838-50
pubmed: 25226613

Auteurs

Han-Li Huang (HL)

TMU Biomedical Commercialization Center, Taipei Medical University, Taipei 11031, Taiwan.
Ph.D Program in Biotechnology Research and Development, College of Pharmacy, Taipei Medical University, Taipei 11031, Taiwan.

Yi-Min Liu (YM)

TMU Biomedical Commercialization Center, Taipei Medical University, Taipei 11031, Taiwan.

Ting-Yi Sung (TY)

Ph.D Program in Biotechnology Research and Development, College of Pharmacy, Taipei Medical University, Taipei 11031, Taiwan.

Tsui-Chin Huang (TC)

Graduate Institute of Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.

Ya-Wen Cheng (YW)

Graduate Institute of Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.

Jing-Ping Liou (JP)

TMU Biomedical Commercialization Center, Taipei Medical University, Taipei 11031, Taiwan.
School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 11031, Taiwan.

Shiow-Lin Pan (SL)

TMU Biomedical Commercialization Center, Taipei Medical University, Taipei 11031, Taiwan.
Ph.D Program in Biotechnology Research and Development, College of Pharmacy, Taipei Medical University, Taipei 11031, Taiwan.
Graduate Institute of Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH